Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3278371
Max Phase: Preclinical
Molecular Formula: C48H75N15O14
Molecular Weight: 1086.22
Molecule Type: Protein
Associated Items:
ID: ALA3278371
Max Phase: Preclinical
Molecular Formula: C48H75N15O14
Molecular Weight: 1086.22
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Standard InChI: InChI=1S/C48H75N15O14/c1-24(2)17-30(42(72)58-29(7-5-15-53-48(51)52)47(77)63-16-6-8-35(63)46(76)54-21-37(50)67)57-39(69)22-55-40(70)32(19-26-9-11-27(65)12-10-26)60-45(75)34(23-64)62-44(74)33(20-36(49)66)61-43(73)31(18-25(3)4)59-41(71)28-13-14-38(68)56-28/h9-12,24-25,28-35,64-65H,5-8,13-23H2,1-4H3,(H2,49,66)(H2,50,67)(H,54,76)(H,55,70)(H,56,68)(H,57,69)(H,58,72)(H,59,71)(H,60,75)(H,61,73)(H,62,74)(H4,51,52,53)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
Standard InChI Key: AHZVQABXAUDKAM-DZCXQCEKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1086.22 | Molecular Weight (Monoisotopic): 1085.5618 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Humphries J, Wan YP, Folkers K.. (1977) Inhibition of the activity of the luteinizing hormone-releasing hormone (LH-RH) by analogues with variations at positions 2, 3, and 6 and the carboxyl terminus., 20 (7): [PMID:327068] [10.1021/jm00217a024] |
Source(1):